You are viewing an incomplete version of our website. Please click to reload the website as full version.

FXYD5 antibody (FXYD Domain Containing Ion Transport Regulator 5) (AA 70-100)

Details for Product anti-FXYD5 Antibody No. ABIN952009, Supplier: Log in to see
Antigen
  • DYSAD
  • EF-8
  • FXYD5
  • IWU1
  • KCT1
  • Oit2
  • OIT2
  • PRO6241
  • RIC
Epitope
AA 70-100, Middle Region
18
15
15
9
4
3
2
1
Reactivity
Human
61
1
1
1
Host
Rabbit
46
15
Clonality
Polyclonal
Conjugate
This FXYD5 antibody is un-conjugated
3
3
3
3
3
3
Application
Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
50
31
20
8
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen KLH conjugated synthetic peptide between 70-100 amino acids from the Central region of Human Dysadherin / FXYD5
Isotype Ig
Specificity This antibody recognizes Human Dysadherin / FXYD5 (Center).
Purification Protein A column, followed by peptide affinity purification
Alternative Name Dysadherin / FXYD5 (FXYD5 Antibody Abstract)
Background This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu.].Synonyms: DYSAD, FXYD domain-containing ion transport regulator 5, IWU1
Gene ID 53827
NCBI Accession NP_001158077
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer PBS containing 0.09 % (W/V) Sodium Azide as preservative
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Supplier Images
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) image for anti-FXYD5 antibody (FXYD Domain Containing Ion Transport Regulator 5) (AA 70-100) (ABIN952009) Immunohistochemistry analysis in formalin fixed and paraffin embedded human rectum ti...
Western Blotting (WB) image for anti-FXYD5 antibody (FXYD Domain Containing Ion Transport Regulator 5) (AA 70-100) (ABIN952009) Western blot analysis of Dysadherin / FXYD5 Antibody (Center) in CEM cell line lysate...
Background publications Ono, Uramoto, Hanagiri: "Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC." in: Anticancer research, Vol. 30, Issue 9, pp. 3273-8, 2010 (PubMed).

Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).

Liang, Zheng, Xiao, Li, Cheng, Wang: "Dysadherin expression in gastrointestinal stromal tumors (GISTs)." in: Pathology, research and practice, Vol. 205, Issue 7, pp. 445-50, 2009 (PubMed).

Talmud, Drenos, Shah, Shah, Palmen, Verzilli, Gaunt, Pallas, Lovering, Li, Casas, Sofat, Kumari, Rodriguez, Johnson, Newhouse, Dominiczak, Samani, Caulfield, Sever, Stanton, Shields, Padmanabhan et al.: "Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. ..." in: American journal of human genetics, Vol. 85, Issue 5, pp. 628-42, 2009 (PubMed).

Batistatou, Charalabopoulos, Nakanishi, Vagianos, Hirohashi, Agnantis, Scopa: "Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin." in: Endocrine pathology, Vol. 19, Issue 3, pp. 197-202, 2008 (PubMed).